Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Algeta
Algeta
Activities:
Manufacturing
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Pharmaceutical
Thomas Ramdahl appointed as Managing Director of Algeta
Bayer has completed the acquisition of the Norwegian developer of cancer drugs
Research & Development
Algeta appoints Chief Scientific Officer
Dr Andreas Menrad takes responsibility for the Norwegian company\'s research strategy
Manufacturing
Algeta opens commercial production facility for Xofigo in Norway
The plant for the manufacture of the cancer treatment is based at the Institute for Energy Technology (IFE) in Norway
Manufacturing
Cobra Biologics and Algeta sign monoclonal antibody manufacturing agreement
Cobra to provide cell line development, cell banking, process development, scale-up, GMP production and stability studies
Norwegian cancer therapeutics developer appoints president
Jeffrey Albers takes up the role at Algeta US
Regulatory
Anticancer agent – radium-223 chloride
Radiotherapy commonly involves directing beams of radioactive particles at the tumour, or a radioactive source being placed within the body
Research & Development
Algeta wins grant to develop alpha-pharmaceuticals based on Thorium-227
Norwegian firm to create pipeline of cancer-destroying drugs
Subscribe now